BOSTON, Oct. 2, 2018 /PRNewswire/ -- The journal Aging published the research conducted by CureLab Oncology, Inc. The paper demonstrates that a new biological agent developed by the company may prevent and alleviate age-related macular degeneration (AMD). AMD is a leading cause of age related blindness.
"Although we may not reverse the signs of already existing AMD, we can dramatically slow down its progression so millions of people will see the beauty of the world for years longer than doctors predict for them today" - said CureLab Oncology founder, Prof. Alexander Shneider, a senior author of the paper.
The work was performed on rapidly aging rats used to test anti-blindness agents. "I have never seen the effect of an anti-AMD drug remain for so long after we stop administering it. In contrast, usually we face a severe withdrawal effect." – Says Prof. Kolosova, the first author on the paper.
AMD involves a complex interplay of genetic and environmental factors. Age-related alterations in the immune system, inflammation and oxidative stress strongly interwoven into AMD pathogenesis. CureLab Oncology's product, circular DNA encoding p62/SQSTM1 gene, reduces chronic inflammation, preventing and treating diseases resulting from it such as metabolic syndrome, osteoporosis, ALS, multiple sclerosis, psoriasis, and potentially many others. Thus, Prof. Shneider, has hypothesized that the product would prevent and reduce the severity of AMD too. The data suggests that the new biological agent may act via multiple mutually complementing mechanisms beyond the original hypothesis. This new application of the drug became a subject of a patent application.
Although the majority of anti-AMD drugs require intraocular administration, the CureLab Oncology product is injected intramuscularly. Italian co-author on the paper, prof. Franco Venanzi of University of Camerino, is creating its eatable form.
The paper is available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128417/
About CureLab Oncolgoy, Inc.:
CureLab Oncology, Inc. is a Boston based private biotechnology company developing biological agents against cancer and chronic inflammation. The company conducted a phase I/IIa clinical trial demonstrating high safety and promising clinical benefits especially evident for breast and ovarian cancer patients.
In the ongoing case study, the product, ElenagenTM, acts as a potent adjuvant to chemotherapy. The product is available to cancer patients under Right to Try law.
For more information please visit www.CureLabOncology.com
Contact: Aaron Shneider
EMAIL: [email protected]
PHONE EXT. +1-609-841-1201
Advertisement
"Although we may not reverse the signs of already existing AMD, we can dramatically slow down its progression so millions of people will see the beauty of the world for years longer than doctors predict for them today" - said CureLab Oncology founder, Prof. Alexander Shneider, a senior author of the paper.
Advertisement
The work was performed on rapidly aging rats used to test anti-blindness agents. "I have never seen the effect of an anti-AMD drug remain for so long after we stop administering it. In contrast, usually we face a severe withdrawal effect." – Says Prof. Kolosova, the first author on the paper.
AMD involves a complex interplay of genetic and environmental factors. Age-related alterations in the immune system, inflammation and oxidative stress strongly interwoven into AMD pathogenesis. CureLab Oncology's product, circular DNA encoding p62/SQSTM1 gene, reduces chronic inflammation, preventing and treating diseases resulting from it such as metabolic syndrome, osteoporosis, ALS, multiple sclerosis, psoriasis, and potentially many others. Thus, Prof. Shneider, has hypothesized that the product would prevent and reduce the severity of AMD too. The data suggests that the new biological agent may act via multiple mutually complementing mechanisms beyond the original hypothesis. This new application of the drug became a subject of a patent application.
Although the majority of anti-AMD drugs require intraocular administration, the CureLab Oncology product is injected intramuscularly. Italian co-author on the paper, prof. Franco Venanzi of University of Camerino, is creating its eatable form.
The paper is available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128417/
About CureLab Oncolgoy, Inc.:
CureLab Oncology, Inc. is a Boston based private biotechnology company developing biological agents against cancer and chronic inflammation. The company conducted a phase I/IIa clinical trial demonstrating high safety and promising clinical benefits especially evident for breast and ovarian cancer patients.
In the ongoing case study, the product, ElenagenTM, acts as a potent adjuvant to chemotherapy. The product is available to cancer patients under Right to Try law.
For more information please visit www.CureLabOncology.com
Contact: Aaron Shneider
EMAIL: [email protected]
PHONE EXT. +1-609-841-1201
View original content:http://www.prnewswire.com/news-releases/curelab-oncology-publishes-proof-of-concept-demonstrating-that-its-product-can-reduce-the-leading-cause-of-age-related-blindness-300722164.html
SOURCE CureLab Oncology, Inc.
